Marseille

• Comparison FOLFIRINOX Panitumumab vs mFOLFOX6 Panitumumab in RAS/B-RAF Wild-type Metastatic Colorectal Cancer Patients (PANIRINOX) Ended recruitment
  2024-510645-34-00 4 2017-06-28 RAS and B-RAF wild-type metastatic colorectal cancer. RAS and B-RAF mu
• A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors Ended recruitment
  2023-506390-35-00 1 2017-04-19 Patients with Advanced Solid Tumors
• IRinotecan and Oxaliplatin for Colon Cancer in Adjuvant Setting Ended recruitment
  2024-517489-41-00 5 2017-03-27 High-risk stage III colon cancer
• PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection Ended recruitment
  2024-510704-37-00 5 2017-03-22 ER+/HER2- metastatic breast cancer
• Comparing two treatment regimen for sinuses tumors and salivary glands: radiotherapy versus chemoradiotherapy Ended recruitment
  2024-513972-16-00 5 2017-01-30 - Resected tumors of sinuses or salivary glands - Non-operable tumors
• Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Expos … Ended recruitment
  2022-501763-40-00 5 2016-12-13 Pre-Exposure Prophylaxis of HIV-1 Infection
• A Long Term Safety Study of ND0612 Administered as a Continuous SC Infusion in Advanced Parkinson’s Disease (BeyoND) Ended recruitment
  2024-513548-27-00 4 2016-10-05 Parkinson's disease
• A Phase Ib-II Study of tazemetostat (EPZ-6438) in newly diagnosed Diffuse Large B Cell Lymphoma (DLBCL) or high risk Follicular Lymphoma (FL … Ended recruitment
  2024-515846-18-00 7 2016-09-19 Newly diagnosed Diffuse Large B Cell Lymphoma
• Study of Tumor Alterations Responsive to Targeting Receptor Kinases-2 Ended recruitment
  2023-505034-10-00 4 2016-08-01 Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS
• Neoadjuvant L19IL2/L19TNF- Pivotal study Ended recruitment
  2024-515749-40-00 5 2016-02-25 Malignant melanoma of the skin in patients with locally advanced and f
• An Efficacy and Safety Study of JNJ56021927 (ARN509) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS Ended recruitment
  2023-505246-26-00 5 2016-01-27 High- or very-high risk, localized or locally advanced prostate cancer
• EORTC-1407-GUCG: A randomized phase III trial comparing conventional-dose chemotherapy using paclitaxel, ifosfamide, and cisplatin (TIP) wit … Ended recruitment
  2024-513509-30-00 5 2016-01-11 Progressive or recurrent germ cell tumor (measurable or non-measurable
• Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lun … Ended recruitment
  2023-505981-26-00 5 2015-11-20 Non−Small Cell Lung Cancer
• RANDOMIZED STUDY COMPARING SENTINEL NODE POLICY TO CURRENT INITIAL STAGING PROTOCOLS IN EARLY STAGE ENDOMETRIAL CARCINOMAS AT INTERMEDIATE A … Ended recruitment
  2024-513079-42-00 5 2015-11-19 Intermediate-risk, high risk endometrial cancer
• Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage … Ended recruitment
  2023-509136-25-00 5 2015-07-16 Stage III melanoma (AJCC R0) with histologically confirmed cutaneous m
• Phase I/II study to evaluate the efficacy and safety of PAZOPANIB in combination with TEMOZOLOMIDE as maintenance therapy in Glioblastoma pa … Ended recruitment
  2024-510960-22-00 9 2015-06-25 gliobastoma
• PRODIGE 34 - ADAGE: Randomised phase III study evaluating adjuvant chemotherapy after resection of stage III colon adenocarcinoma in patient … Ended recruitment
  2024-518741-21-00 4 2014-12-23 colon cancer
• A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer (JUNIPER) Ended recruitment
  2023-506779-82-00 5 2014-11-04 Non Small Cell Lung Cancer
• A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas (REGOBONE) Ended recruitment
  2024-513455-33-00 4 2014-09-11 Bone sarcoma
• Olaparib as adjuvant treatment in patients with germline BRCA mutated high risk HER2negative primary breast cancer. Ended recruitment
  2024-511096-15-00 5 2014-08-01 Breast Cancer
• A phase Ib/II, multicenter, study of the combination of LEE011 and BYL719 with letrozole in adult patients with advanced ER+ breast cancer Ended recruitment
  2023-509511-84-00 9 2014-03-19 Advanced HR+ breast cancer
• A large-scale comparative study evaluating an intravenous treatment, cabazitaxel, and radiation therapy to the pelvic lymph nodes in patient … Ended recruitment
  2024-517622-25-00 5 2013-12-06 Patients with localized prostate cancer and high-risk features of rela
• A two-year, double-blind, randomized, multicenter, active controlled Core Phase study to evaluate the safety and efficacy of fingolimod admi … Ended recruitment
  2023-507556-68-00 5 2013-07-26 Multiple Sclerosis
• Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free … Ended recruitment
  2024-516198-61-00 5 2013-06-05 Patients with high risk of relapse, ER+ and HER2- primary non-metastat

Showing 1,201–1,224 of 1,520 trials